Candidate Compounds Covid19

(Unterschied zwischen Versionen)

Wechseln zu: Navigation, Suche

Version vom 28. Juni 2020, 09:50 Uhr

coviki.org collects the really good Ideas and the scientific Record on Covid-19 Virus.

current items will be put into the subsections.

other single compounds
Retargeted single compounds
Hydroxychloroquine
Target ACE2, Spike protein
Target TMPRSS2, Spike protein any other covid targed herein
other antiviral compounds
AV Remdesivir
AV Lopinavir
AV Ivermectin
AV Arabidol
AV Favipiravir

Immunodeviation e.g. by adjuvants or other vaccinations
Radiation therapy
Phototherapy
Active vaccine

008

32458400 2020. Implications for Neuromodulation Therapy to Control Inflammation and Related Organ Dysfunction in COVID-19.

32401611 2020. The pulmonary-proteoliposome as a new therapeutic approach for Coronaviruses.

32413736 2020. Towards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, and corticosteroids.

32450201 2020. Side effects of ruxolitinib in patients with SARS-CoV-2 infection: Two case reports.
32522674 2020. Widely available lysosome targeting agents should be considered as potential therapy for COVID-19.

32534188 2020. Severe Acute Respiratory Syndrome Coronavirus -2 (SARS-CoV-2): A global pandemic and treatments strategies.

32534094 2020. Antiviral activity of the high-molecular-weight plant polysaccharides (Panavir(R)).

32460369 2020. Non-steroidal anti-inflammatory drugs in management of COVID-19; A systematic review on current evidence.
32412158 2020. Indomethacin and resveratrol as potential treatment adjuncts for SARS-CoV-2/COVID-19.
32531935 2020. Chronic Inflammation in the Context of Everyday Life: Dietary Changes as Mitigating Factors.

32411575 2020. Malnutrition Care during the COVID-19 Pandemic: Considerations for Registered Dietitian Nutritionists Evidence Analysis Center.

32470486 2020. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial.

32527713 2020. In Silico computational screening of Kabasura Kudineer - Official Siddha Formulation and JACOM against SARS-CoV-2 spike protein.

32396773 2020. Truncated human angiotensin converting enzyme 2; a potential inhibitor of SARS-CoV-2 spike glycoprotein and potent COVID-19 therapeutic agent.

32384202 2020. Home-based training strategy to maintain muscle function in older adults with diabetes during COVID-19 confinement.

32509284 2020. The need to implement non-industry COVID-19 clinical trials in non-high-income countries.

32533263 2020. Intracellular ABCB1 as a Possible Mechanism to Explain the Synergistic Effect of Hydroxychloroquine-Azithromycin Combination in COVID-19 Therapy.

32469114 2020. An update on ACE2 amplification and its therapeutic potential.

32315803 2020. Preliminary therapeutic drug monitoring data of beta-lactams in critically ill patients with SARS-CoV-2 infection.

32519894 2020. Heparin as a Therapy for COVID-19: Current Evidence and Future Possibilities.

32499129 2020. Immunotherapies for COVID-19: Restoring the immunity could be the priority.

32534022 2020. COVID-19 and allergen immunotherapy: theoretical benefits invite to adjustments in practice recommendations.

32405693 2020. Could ruxolitinib be effective in patients with COVID-19 infection at risk of acute respiratory distress syndrome (ARDS)?

32345532 2020. Response to: Bioactive Lipids and Coronavirus (COVID-19)-further Discussion.

32399093 2020. Lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic.

32470547 2020. Targeting Neprilysin (NEP) pathways: A potential new hope to defeat COVID-19 ghost.

32532623 2020. Fighting COVID-19: A quick review of diagnoses, therapies, and vaccines.

32383371 2020. Perspectives of Immune Therapy in Coronavirus Disease 2019.

32401215 2020. Telehealth Home Support During COVID-19 Confinement for Community-Dwelling Older Adults With Mild Cognitive Impairment or Mild Dementia: Survey Study.

32468385 2020. Musings on the current state of COVID-19 modeling and reporting.
32435882 2020. Model based approach for estimating the dosage regimen of indomethacin a potential antiviral treatment of patients infected with SARS CoV-2.

32452670 2020. Immunity-Boosting Spices and the Novel Coronavirus.

32396382 2020. Myth Busters: Dietary Supplements and COVID-19.

32523144 2020. Protocolo para la prevencion de arritmias ventriculares debido al tratamiento en pacientes con COVID-19.
32518135 2020. Paediatric treatment trials for COVID-19 are an ethical imperative.
32522067 2020. Autophagy as an emerging target for COVID-19: lessons from an old friend, chloroquine.
32521191 2020. Open questions for harnessing autophagy-modulating drugs in the SARS-CoV-2 war: hope or hype?
32515023 2020. A call for the appropriate application of clinical pharmacological principles in the search for safe and efficacious COVID-19 (SARS-COV-2) treatments.

32520031 2020. In silico evaluation of marine fish proteins as nutritional supplements for COVID-19 patients.

32516380 2020. Covid-19's Impact on Podiatry in Chicago's Largest Public Hospital.

32390307 2020. Practical tips for using masks in the COVID-19 pandemic.
32358890 2020. Cutaneous side-effects of the potential COVID-19 drugs.

32428864 2020. Angiotensin converting enzyme-2 as therapeutic target in COVID-19.

32514859 2020. Drug-Induced Liver Injury and COVID-19 Infection: The Rules Remain the Same.

32378805 2020. COVID-19 and toxicity from potential treatments: Panacea or poison.
32475694 2020. Reflexions autour d'une evolution favorable d'une COVID-19 chez un patient presentant une schizophrenie resistante et sous une association clozapine et paliperidone palmitate.
32482569 2020. Nutricion Clinica en tiempos de COVID-19.

32518390 2020. Editorial: Nutrition and COVID-19.
32433599 2020. Nutritional management of COVID-19 patients in a rehabilitation unit.
32404899 2020. Clinical significance of nutritional risk screening for older adult patients with COVID-19.

32398309 2020. Could the smoking gun in the fight against Covid-19 be the (rh) ACE2?

32398976 2020. siRNA could be a potential therapy for COVID-19.

32425923 2020. Could the Inhibition of Endo-Lysosomal Two-Pore Channels (TPCs) by the Natural Flavonoid Naringenin Represent an Option to Fight SARS-CoV-2 Infection?

32468851 2020. Facing the SARS-CoV-2 outbreak in the immunotherapy era.
32406749 2020. Oncology clinical trials in the time of COVID-19: how a pandemic can revolutionize patients' care.

32535509 2020. COVID-19, interferons, and depression: A commentary.

32470338 2020. MORTALITY FROM COVID-19 INCREASES WITH UNSATURATED FAT, AND MAY BE REDUCED BY EARLY CALCIUM AND ALBUMIN SUPPLEMENTATION.

007

32496248 2020. Effectiveness of preventive measures against COVID-19: A systematic review of In Silico modeling studies in indian context.
32496246 2020. Impact of nonpharmacological interventions on COVID-19 transmission dynamics in India.

32429572 2020. The Role of Lipid Metabolism in COVID-19 Virus Infection and as a Drug Target.

32408699 2020. Essential Oils as Antiviral Agents. Potential of Essential Oils to Treat SARS-CoV-2 Infection: An In-Silico Investigation.

32455942 2020. Potential Therapeutic Targeting of Coronavirus Spike Glycoprotein Priming.

32457038 2020. Potential COVID-19 therapeutics from a rare disease: Weaponizing lipid dysregulation to combat viral infectivity.

32423974 2020. COVID-19 and Rheumatology patients on immunomodulatory therapy - can we extrapolate data from previous viral pandemics?

32475104 2020. Coronavirus Disease 2019 Presenting as Conjunctivitis.

32162896 2020. Possible therapeutic role of a highly standardized mixture of active compounds derived from cultured Lentinula edodes mycelia (AHCC) in patients infected with 2019 novel coronavirus.

32418757 2020. Pancreatic cancer: Does a short course of carbon ion radiotherapy worth during COVID-19 outbreak?

32505040 2020. The end of 'cordon sanitaire' in Wuhan: the role of non-pharmaceutical interventions against COVID-19.

32472939 2020. Assessing the impact of non-pharmaceutical interventions on SARS-CoV-2 transmission in Switzerland.

32500793 2020. Repurposing Nimesulide, a Potent Inhibitor of the B0AT1 Subunit of the SARS-CoV-2 Receptor, as a Therapeutic Adjuvant of COVID-19.

32491981 2020. Nonpharmaceutical Measures for Pandemic Influenza in Nonhealthcare Settings-International Travel-Related Measures.
32487283 2020. Effect of Nonpharmaceutical Interventions on Transmission of Severe Acute Respiratory Syndrome Coronavirus 2, South Korea, 2020.

32403995 2020. Development of multi-specific humanized llama antibodies blocking SARS-CoV-2/ACE2 interaction with high affinity and avidity.

32496237 2020. AYUSH for COVID-19: Science or Superstition?

32460209 2020. The effect of potential therapeutic agents on QT interval in patients with COVID-19 Infection: The importance of close monitoring and correction of electrolytes.

32487990 2020. Modeling mitigation of influenza epidemics by baloxavir.

32438383 2020. Inhaled modified angiotensin converting enzyme 2 (ACE2) as a decoy to mitigate SARS-CoV-2 infection.

32512579 2020. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe.

32501634 2020. Can Hypericum perforatum (SJW) prevent cytokine storm in COVID-19 patients?

32116200 2020. COVID-19: Perspectives on the Potential Novel Global Threat.

32294756 2020. Intervencoes nao farmacologicas para o enfrentamento a epidemia da COVID-19 no Brasil.

32448098 2020. Structural and simulation analysis of hotspot residues interactions of SARS-CoV 2 with human ACE2 receptor.

32458425 2020. Compassionate use of hzVSF-v13 in two patients with severe COVID-19.

32463459 2020. Prescription Fill Patterns for Commonly Used Drugs During the COVID-19 Pandemic in the United States.

32498081 2020. Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).

32310670 2020. Public Health Approach of Ayurveda and Yoga for COVID-19 Prophylaxis.

32462858 2020. Oxygen-ozone therapy as adjuvant in the current emergency in SARS-COV-2 infection: a clinical study.
32469279 2020. Withanone and Withaferin-A are predicted to interact with transmembrane protease serine 2 (TMPRSS2) and block entry of SARS-CoV-2 into cells.

32462988 2020. A computational prediction of SARS-CoV-2 structural protein inhibitors from Azadirachta indica (Neem).

32475223 2020. Antiviral effects of probiotic metabolites on COVID-19.
32462970 2020. Identification of potential inhibitors of SARS-COV-2 endoribonuclease (EndoU) from FDA approved drugs: a drug repurposing approach to find therapeutics for COVID-19.

32462996 2020. Molecular docking, simulation and MM-PBSA studies of nigella sativa compounds: a computational quest to identify potential natural antiviral for COVID-19 treatment.

32476574 2020. Virtual screening-driven drug discovery of SARS-CoV2 enzyme inhibitors targeting viral attachment, replication, post-translational modification and host immunity evasion infection mechanisms.
32485061 2020. Incidence and Determinants of QT Interval Prolongation in COVID-19 Patients Treated with Hydroxychloroquine and Azithromycin.

32433345 2020. The pharmacological development of direct acting agents for emerging needed therapy against SARS-CoV-2.

32473011 2020. Potential inhibition of COVID-19-driven pneumonia by immunosuppressive therapy and anti-TNFalpha antibodies: a case report.
32504739 2020. Interleukin-17: A potential therapeutic target in COVID-19.
32473010 2020. TPE-nAbs combination therapy for severe COVID-19.
32220033 2020. Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19).

32511912 2020. COVID-19: Drug targets and potential treatments.
32469301 2020. Potential RNA-dependent RNA polymerase inhibitors as prospective therapeutics against SARS-CoV-2.

32472703 2020. COVID-19 pneumonia treated with Sarilumab: A clinical series of eight patients.
32427773 2020. Rescue Therapy for Severe COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) with Tissue Plasminogen Activator (tPA): A Case Series.
32364561 2020. Randomized Clinical Trials and COVID-19: Managing Expectations.
32463427 2020. Using Controlled Trials to Resolve Key Unknowns About Policy During the COVID-19 Pandemic.
32453363 2020. No Benefit for Lopinavir-Ritonavir in Severe COVID-19.

32506195 2020. Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19.

32463794 2020. Metformin and SARS-CoV-2: mechanistic lessons on air pollution to weather the cytokine/thrombotic storm in COVID-19.

32434272 2020. COVID-19Clinical trials: quality matters more than quantity.

32464736 2020. A simulation training course for family medicine residents in China managing COVID-19.
32505821 2020. Analysis of the molecular mechanism of Pudilan (PDL) treatment for COVID-19 by network pharmacology tools.

32455629 2020. Tripartite Combination of Candidate Pandemic Mitigation Agents: Vitamin D, Quercetin, and Estradiol Manifest Properties of Medicinal Agents for Targeted Mitigation of the COVID-19 Pandemic Defined by Genomics-Guided Tracing of SARS-CoV-2 Targets in Human Cells.

32398343 2020. Should azithromycin be used to treat COVID-19? A rapid review.

32454500 2020. Extracorporeal Blood Purification and Organ Support in the Critically Ill Patient during COVID-19 Pandemic: Expert Review and Recommendation.
32453693 2020. Rebuttal to letter "Is thromboprophylaxis with high-dose enoxaparin really necessary for COVID-19 patients? A new "prudent" randomised clinical trial".
32453692 2020. Is thromboprophylaxis with high-dose enoxaparin really necessary for COVID-19 patients? A new "prudent" randomised clinical trial.

32267762 2020. Research towards treating COVID-19.

32433778 2020. Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19.
32442317 2020. The case for Chronotherapy in COVID-19 induced Acute Respiratory Distress Syndrome (ARDS).
32441783 2020. A rationale for targeting the P2X7 receptor in Coronavirus disease 19 (Covid-19).
32441764 2020. Repositioning PARP inhibitors for SARS-CoV-2 infection (COVID-19); a new multi-pronged therapy for ARDS?
32424836 2020. Lung tissue distribution of drugs as a key factor for COVID-19 treatment.
32449802 2020. May we target double membrane vesicles and oxysterol-binding protein to combat SARS-CoV-2 infection?
32512007 2020. Efficacy of Almitrine in The Treatment of Hypoxemia in Sars-Cov-2 Acute Respiratory Distress Syndrome.
32445484 2020. A Real-World Evidence Framework for Optimising Dosing in All Patients with COVID-19.
32438446 2020. Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics.
32508009 2020. Thalidomide combined with low-dose short-term glucocorticoid in the treatment of critical Coronavirus Disease 2019.
32441462 2020. Time to Step Up: A Call to Action For the Clinical and Quantitative Pharmacology Community to Accelerate Therapeutics for COVID-19.
32511867 2020. Predictions of Systemic, Intracellular, and Lung Concentrations of Azithromycin with Different Dosing Regimens used in COVID-19 Clinical Trials.
32418327 2020. Ligand-centered assessment of SARS-CoV-2 drug target models in the Protein Data Bank.

32449939 2020. SARS-CoV-2 spike glycoprotein-binding proteins expressed by upper respiratory tract bacteria may prevent severe viral infection.

32420947 2020. Stop playing with data: there is no sound evidence that Bacille Calmette-Guerin may avoid SARS-CoV-2 infection (for now).
32420936 2020. Treatments for COVID-19: emerging drugs against the coronavirus.
32425152 2020. Medicines for the Treatment Of COVID-19: Awaiting the Evidence.
32506621 2020. Drugs being investigated for children with COVID-19.

32423954 2020. Accelerating drug development through repurposed FDA approved drugs for COVID-19: speed is important, not haste.

32493028 2020. Letter to the Editor: Repurposing of an Antisepsis Drug in COVID-19 Patients.

32510142 2020. alpha-glucosidase inhibitors as host-directed antiviral agents with potential for the treatment of COVID-19.
32407491 2020. iBioProVis: Interactive Visualization and Analysis of Compound Bioactivity Space.

32403134 2020. Combination dose-escalated hydroxyurea and transfusion: an approach to conserve blood during the COVID-19 pandemic.
32345591 2020. RECOVERY trial: the UK covid-19 study resetting expectations for clinical trials.
32303505 2020. Covid-19: ibuprofen can be used for symptoms, says UK agency, but reasons for change in advice are unclear.
32407551 2020. Interrogation of the safety and efficacy of home-use light-based devices.

32480418 2020. Harnessing HLA-E-restricted CD8 T lymphocytes for adoptive cell therapy of severe COVID-19 patients.

32498751 2020. Drug Repurposing for COVID-19: Ethical Considerations and Roadmaps.

32429705 2020. COVID-19 and Nutrition: The Need for Initiatives to Promote Healthy Eating and Prevent Obesity in Childhood.
32412788 2020. beta-Arrestin-Biased Angiotensin II Receptor Agonists for COVID-19.
32503806 2020. The World of Clinical Trial Development Post-Covid-19: Lessons Learned from a Global Pandemic.
32474583 2020. In Reply: COVID-19: An Argument for Rapid Access to Laboratory Data Warehouses.
32459003 2020. A role for retinoids in the treatment of COVID-19?

32459832 2020. Importance of Pediatric Inclusion in COVID-19 Therapeutic Trials.
32442287 2020. Thymosin alpha 1 (Talpha1) reduces the mortality of severe COVID-19 by restoration of lymphocytopenia and reversion of exhausted T cells.

32498131 2020. Pandemic Best Regulatory Practices: An Urgent Need in the Covid-19 Pandemic.

32350861 2020. COVID-19: A Defining Moment for Clinical Pharmacology?
32442315 2020. Alternative splicing of ACE2 possibly generates variants that may limit the entry of SARS-CoV-2: a potential therapeutic approach using SSOs.

32212378 2020. Optimizing COVID-19 Candidate Therapeutics: Thinking Without Borders.

32284037 2020. Perspective on the COVID-19 Coronavirus Outbreak.
32174284 2020. A Generic Computer-Assisted Four-Pronged Approach for the Management of Emerging Global Pathogens: Some Comments on COVID-19.
32400323 2020. In vitro data of current therapies for SARS-CoV-2.
32427000 2020. Implications of the lack of a unified research project framework: an investigation into the registration of clinical trials of COVID-19.

32416679 2020. Novel Drugs Targeting the SARS-CoV-2/COVID-19 Machinery.
32394841 2020. COVID-19: An Update on Clinical Trials.
32282303 2020. Coronavirus Disease (COVID-19) Pandemic: A Race Against Time.
32475041 2020. Potential role of Anti-IL-17 in COVID-19 treatment.
32473070 2020. Treatment of COVID-19 with pentoxifylline: Could it be a potential adjuvant therapy?
32510814 2020. Omalizumab and COVID19 Treatment: Could It Help?
32510734 2020. Azithromycin and COVID-19Prompt Early Use at First Signs of this Infection in Adults and Children An Approach Worthy of Consideration.
32510719 2020. Intramatricial methotrexate for treatment of resistant acrodermatitis continua of Hallopeau: an alterative in Covid-19.
32500633 2020. "Thinking outside the box in COVID-19 era"-Application of Modified Aerosol Box in Dermatology.
32419517 2020. Emerging therapies for COVID-19 pneumonia.
32429703 2020. SARS, MERS and SARS-CoV-2 (COVID-19) treatment: a patent review.
32419524 2020. Old and re-purposed drugs for the treatment of COVID-19.
32223349 2020. How could artificial intelligence aid in the fight against coronavirus?

32500928 2020. COVID-19 breakthroughs: separating fact from fiction.

32419212 2020. Granulocyte-colony stimulating factor in COVID-19: Is it stimulating more than just the bone marrow?

32401673 2020. Urgent reconsideration of lung edema as a preventable outcome in COVID-19: inhibition of TRPV4 represents a promising and feasible approach.

32428965 2020. Exclusion of Pregnant Women from Clinical Trials during the Coronavirus Disease 2019 Pandemic: A Review of International Registries.
32479158 2020. Reply to Jakovac; Severity of COVID-19 infection in patients with phenylketonuria: is vitamin D status protective?
32464083 2020. P-selectin blockade in COVID-19-related ARDS.
32437628 2020. COVID-19, Asthma, and Inhaled Corticosteroids (ICS): Another Beneficial Effect of ICS?

32446312 2020. Metformin Treatment Was Associated with Decreased Mortality in COVID-19 Patients with Diabetes in a Retrospective Analysis.
32503855 2020. Candidate rheumatologic treatments for COVID-19. Response to: 'COVID-19 infection in a patient with FMF: does colchicine have a protective effect?' by Kobak.

32340978 2020. The conundrum of COVID-19 treatment targets: the close correlation with rheumatology. Response to: 'Management of rheumatic diseases in the time of covid-19 pandemic: perspectives of rheumatology pracitioners from India' by Gupta et al and 'Antirheumatic agents in covid-19: is IL-6 the right target?' by Capeechi et al. -rest-
32229705 2020. Geroprotective and senoremediative strategies to reduce the comorbidity, infection rates, severity, and lethality in gerophilic and gerolavic infections
32276453 2020. Exploring the Relevance of Senotherapeutics for the Current SARS-CoV-2 Emergency and Similar Future Global Health Threats
32325124 ä. Vaporization, bioactive formulations and a marine natural product: different perspectives on antivirals
32312129 2020. The role of additive manufacturing and antimicrobial polymers in the COVID-19 pandemic
32336674 ä. COVID-19 Emergency Responders in FDA?s Center for Drug Evaluation and Research
32356251 ä. Medical Toxicology and COVID-19: Our Role in a Pandemic
32243778 2020. Ensuring global access to COVID-19 vaccines
32247324 2020. Global coalition to accelerate COVID-19 clinical research in resource-limited settings
32272857 2020. Role of Tissue Engineering in COVID-19 and Future Viral Outbreaks
C7190525 2020. Adjunct Immunotherapies for the Management of Severely Ill COVID-19 Patients
32129977 2020. Cell-Membrane-Mimicking Nanodecoys against Infectious Diseases
29115746 2018. Progress Toward the Clinical Translation of Bioinspired Peptide and Protein Assemblies
29717819 2018. Recent Advances in the Development of Antimicrobial Nanoparticles for Combating Resistant Pathogens
C7194243 ä. Coronavirus Disease 2019 (COVID-19) Spread and Pharmacovigilance Implications: Expert Opinion
32383008 ä. The Role of Pharmacovigilance and ISoP During the Global COVID-19 Pandemic
32380052 2020. Granulocyte-targeted therapies for airway diseases
32452420 2020. Antiviral activity of lycorine against Zika virus in vivo and in vitro

Candidate Compounds Covid19

Version vom 28. Juni 2020, 09:50 Uhr

coviki.org collects the really good Ideas and the scientific Record on Covid-19 Virus.

008

007

Meine Werkzeuge

Namensräume

Varianten

Ansichten

Aktionen

Suche

Navigation

Werkzeuge

@@ Zeile 100: / Zeile 100: @@
 {{tp|p=32534094|t=2020. Antiviral activity of the high-molecular-weight plant polysaccharides (Panavir(R)).|pdf=|usr=008}}
-{{tp|p=32435920|t=2020. Lithium's antiviral effects: a potential drug for CoViD-19 disease?|pdf=|usr=008}}
-{{tp|p=32382873|t=2020. Covid-19 and drug therapy, what we learned.|pdf=|usr=008}}
 {{tp|p=32460369|t=2020. Non-steroidal anti-inflammatory drugs in management of COVID-19; A systematic review on current evidence.|pdf=|usr=008}}
 {{tp|p=32412158|t=2020. Indomethacin and resveratrol as potential treatment adjuncts for SARS-CoV-2/COVID-19.|pdf=|usr=008}}
 {{tp|p=32531935|t=2020. Chronic Inflammation in the Context of Everyday Life: Dietary Changes as Mitigating Factors.|pdf=|usr=008}}
-{{tp|p=32470602|t=2020. Three cases of treatment with Nafamostat in elderly patients with COVID-19 pneumonia who need oxygen therapy.|pdf=|usr=008}}
-{{tp|p=32425638|t=2020. Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy - Achieving global consensus and visibility for cellular host-directed therapies.|pdf=|usr=008}}
-{{tp|p=32522597|t=2020. Treatment of SARS-CoV-2 with high dose oral zinc salts: A report on four patients.|pdf=|usr=008}}
-{{tp|p=32502659|t=2020. Potential role of statins in COVID-19.|pdf=|usr=008}}
-{{tp|p=32521619|t=2020. Redox-Modulating Agents in the Treatment of Viral Infections.|pdf=|usr=008}}
-{{tp|p=32461554|t=2020. Colchicine's effects on metabolic and inflammatory molecules in adults with obesity and metabolic syndrome: results from a pilot randomized controlled trial.|pdf=|usr=008}}
-{{tp|p=32327922|t=2020. The 4 D's of Pellagra and Progress.|pdf=|usr=008}}
-{{tp|p=32447429|t=2020. Trials and tribulations: so many potential treatments, so few answers.|pdf=|usr=008}}
-{{tp|p=32483523|t=2020. Characteristics of registered studies for Coronavirus disease 2019 (COVID-19): A systematic review.|pdf=|usr=008}}
-{{tp|p=32426222|t=2020. The Ethics of COVID-19 Clinical Trials: New Considerations in a Controversial Area.|pdf=|usr=008}}
-{{tp|p=32488835|t=2020. Deep Learning Based Drug Screening for Novel Coronavirus 2019-nCov.|pdf=|usr=008}}
-{{tp|p=32458206|t=2020. Potential new treatment strategies for COVID-19: is there a role for bromhexine as add-on therapy?|pdf=|usr=008}}
 {{tp|p=32411575|t=2020. Malnutrition Care during the COVID-19 Pandemic: Considerations for Registered Dietitian Nutritionists Evidence Analysis Center.|pdf=|usr=008}}
-{{tp|p=32479759|t=2020. Successful use of methylprednisolone for treating severe COVID-19.|pdf=|usr=008}}
 {{tp|p=32470486|t=2020. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial.|pdf=|usr=008}}
@@ Zeile 130: / Zeile 123: @@
+{{tp|p=32527713|t=2020. In Silico computational screening of Kabasura Kudineer - Official Siddha Formulation and JACOM against SARS-CoV-2 spike protein.|pdf=|usr=008}}
-{{tp|p=32527713|t=2020. In Silico computational screening of Kabasura Kudineer - Official Siddha Formulation and JACOM against SARS-CoV-2 spike protein.|pdf=|usr=008}}
-{{tp|p=32397940|t=2020. Identification of bioactive molecules from tea plant as SARS-CoV-2 main protease inhibitors.|pdf=|usr=008}}
 {{tp|p=32396773|t=2020. Truncated human angiotensin converting enzyme 2; a potential inhibitor of SARS-CoV-2 spike glycoprotein and potent COVID-19 therapeutic agent.|pdf=|usr=008}}
-{{tp|p=32396769|t=2020. Identification of potential molecules against COVID-19 main protease through structure-guided virtual screening approach.|pdf=|usr=008}}
-{{tp|p=32394467|t=2020. A global treatments for coronaviruses including COVID-19.|pdf=|usr=008}}
-{{tp|p=32526460|t=2020. A large number of COVID-19 interventional clinical trials were registered soon after the pandemic onset: a descriptive analysis.|pdf=|usr=008}}
-{{tp|p=32517353|t=2020. Silibinin and SARS-CoV-2: Dual Targeting of Host Cytokine Storm and Virus Replication Machinery for Clinical Management of COVID-19 Patients.|pdf=|usr=008}}
-{{tp|p=32489508|t=2020. Simultaneous Treatment of COVID-19 With Serine Protease Inhibitor Camostat and/or Cathepsin L Inhibitor?|pdf=|usr=008}}
-{{tp|p=32425662|t=2020. Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: Results from a single Italian Centre study on tocilizumab versus standard of care.|pdf=|usr=008}}
-{{tp|p=32384202|t=2020. Home-based training strategy to maintain muscle function in older adults with diabetes during COVID-19 confinement.|pdf=|usr=008}}
-{{tp|p=32388906|t=2020. Do novel drugs for diabetes help in COVID-19? Another brick in the wall?|pdf=|usr=008}}
-{{tp|p=32495299|t=2020. COVID-19: is there a link between the course of infection and pharmacological agents in diabetes?|pdf=|usr=008}}
-{{tp|p=32398164|t=2020. Drug repurposing against COVID-19: focus on anticancer agents.|pdf=|usr=008}}
+{{tp|p=32384202|t=2020. Home-based training strategy to maintain muscle function in older adults with diabetes during COVID-19 confinement.|pdf=|usr=008}}
 {{tp|p=32509284|t=2020. The need to implement non-industry COVID-19 clinical trials in non-high-income countries.|pdf=|usr=008}}
-{{tp|p=32395245|t=2020. Hypertonic saline nasal irrigation and gargling should be considered as a treatment option for COVID-19.|pdf=|usr=008}}
-{{tp|p=32360293|t=2020. Endothelin receptor antagonists for pulmonary arterial hypertension and COVID-19: Friend or foe?|pdf=|usr=008}}
-{{tp|p=32422152|t=2020. Mesenchymal stem cell therapy in severe COVID-19: A retrospective study of short-term treatment efficacy and side effects.|pdf=|usr=008}}
@@ Zeile 173: / Zeile 162: @@
 {{tp|p=32533263|t=2020. Intracellular ABCB1 as a Possible Mechanism to Explain the Synergistic Effect of Hydroxychloroquine-Azithromycin Combination in COVID-19 Therapy.|pdf=|usr=008}}
-{{tp|p=32405780|t=2020. Research Progress of Drug Treatment in Novel Coronavirus Pneumonia.|pdf=|usr=008}}
-{{tp|p=32383582|t=2020. When the Others Become Us: A Chemist's Perspective of the COVID-19 Outbreak in Italy.|pdf=|usr=008}}
-{{tp|p=32432466|t=2020. Proposed Intranasal Route for Drug Administration in the Management of Central Nervous System Manifestations of COVID-19.|pdf=|usr=008}}
-{{tp|p=32402186|t=2020. Targeting the Dimerization of the Main Protease of Coronaviruses: A Potential Broad-Spectrum Therapeutic Strategy.|pdf=|usr=008}}
-{{tp|p=32428392|t=2020. Characterization and Noncovalent Inhibition of the Deubiquitinase and deISGylase Activity of SARS-CoV-2 Papain-Like Protease.|pdf=|usr=008}}
-{{tp|p=32478500|t=2020. COVID-19 and Other Pandemics: How Might They Be Prevented?|pdf=|usr=008}}
-{{tp|p=32519842|t=2020. Toward Nanotechnology-Enabled Approaches against the COVID-19 Pandemic.|pdf=|usr=008}}
 {{tp|p=32469114|t=2020. An update on ACE2 amplification and its therapeutic potential.|pdf=|usr=008}}
-{{tp|p=32350686|t=2020. Anti COVID-19 Drugs: Need for More Clinical Evidence and Global Action.|pdf=|usr=008}}
-{{tp|p=32454090|t=2020. The preventive strategy for pandemics in the elderly is to collect in advance samples & data to counteract chronic inflammation (inflammaging).|pdf=|usr=008}}
-{{tp|p=32534451|t=2020. Microdose lithium reduces cellular senescence in human astrocytes - a potential pharmacotherapy for COVID-19?|pdf=|usr=008}}
-{{tp|p=32489694|t=2020. Mesenchymal Stem Cells for Coronavirus (COVID-19)-Induced Pneumonia: Revisiting the Paracrine Hypothesis with New Hopes?|pdf=|usr=008}}
-{{tp|p=32489692|t=2020. Adipose Stem Cells (ASCs) and Stromal Vascular Fraction (SVF) as a Potential Therapy in Combating (COVID-19)-Disease.|pdf=|usr=008}}
-{{tp|p=32516203|t=2020. Temporal Improvement of a COVID-19-Positive Crohn's Disease Patient Treated With Bismuth Subsalicylate.|pdf=|usr=008}}
-{{tp|p=32406904|t=2020. Clinical trials: management of investigational products during the coronavirus (COVID-19) pandemic.|pdf=|usr=008}}
-{{tp|p=32479920|t=2020. Erythropoiesis-Stimulating Agent Treatment in Patients With COVID-19.|pdf=|usr=008}}
-{{tp|p=32310688|t=2020. Biological plausibility for interactions between dietary fat, resveratrol, ACE2, and SARS-CoV illness severity.|pdf=|usr=008}}
 {{tp|p=32315803|t=2020. Preliminary therapeutic drug monitoring data of beta-lactams in critically ill patients with SARS-CoV-2 infection.|pdf=|usr=008}}
-{{tp|p=32519895|t=2020. Is targeting Akt a viable option to treat advanced-stage COVID-19 patients?|pdf=|usr=008}}
 {{tp|p=32519894|t=2020. Heparin as a Therapy for COVID-19: Current Evidence and Future Possibilities.|pdf=|usr=008}}
-{{tp|p=32519892|t=2020. Consideration of Pannexin 1 channels in COVID-19 pathology and treatment.|pdf=|usr=008}}
-{{tp|p=32297590|t=2020. Rigorous Randomized Controlled Trial Implementation in the Era of COVID-19.|pdf=|usr=008}}
 {{tp|p=32499129|t=2020. Immunotherapies for COVID-19: Restoring the immunity could be the priority.|pdf=|usr=008}}
-{{tp|p=32505720|t=2020. Positive Outcome in a COVID-19 patient with Common Variable Immunodeficiency after IVIG.|pdf=|usr=008}}
 {{tp|p=32534022|t=2020. COVID-19 and allergen immunotherapy: theoretical benefits invite to adjustments in practice recommendations.|pdf=|usr=008}}
-{{tp|p=32534944|t=2020. Influence of NAD+ as an ageing-related immunomodulator on COVID 19 infection: A hypothesis.|pdf=|usr=008}}
 {{tp|p=32405693|t=2020. Could ruxolitinib be effective in patients with COVID-19 infection at risk of acute respiratory distress syndrome (ARDS)?|pdf=|usr=008}}
-{{tp|p=32436029|t=2020. Nitric oxide inhalation as an interventional rescue therapy for COVID-19-induced acute respiratory distress syndrome.|pdf=|usr=008}}
-{{tp|p=32489437|t=2020. Clinical trials for coronavirus disease 2019: What is being evaluated and what is not.|pdf=|usr=008}}
-{{tp|p=32513797|t=2020. Suramin inhibits SARS-CoV-2 infection in cell culture by interfering with early steps of the replication cycle.|pdf=|usr=008}}
-{{tp|p=32440665|t=2020. Cross-Protection Induced by Encephalitis Vaccines against COVID-19 Might be a Reason for Relatively Lower Mortality Rate in Some Countries.|pdf=|usr=008}}
-{{tp|p=32493626|t=2020. S1 Subunit and Host Proteases as Potential Therapeutic Avenues for the Treatment of COVID-19.|pdf=|usr=008}}
 {{tp|p=32345532|t=2020. Response to: Bioactive Lipids and Coronavirus (COVID-19)-further Discussion.|pdf=|usr=008}}
-{{tp|p=32399097|t=2020. Lessons learned from SARS-CoV and MERS-CoV: FDA-approved Abelson tyrosine-protein kinase 2 inhibitors may help us combat SARS-CoV-2.|pdf=|usr=008}}
-{{tp|p=32399096|t=2020. State-of-the-art tools unveil potent drug targets amongst clinically approved drugs to inhibit helicase in SARS-CoV-2.|pdf=|usr=008}}
-{{tp|p=32399095|t=2020. State-of-the-art tools to identify druggable protein ligand of SARS-CoV-2.|pdf=|usr=008}}
-{{tp|p=32399094|t=2020. Statins and the COVID-19 main protease: in silico evidence on direct interaction.|pdf=|usr=008}}
-{{tp|p=32399093|t=2020. Lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic.|pdf=|usr=008}}
-{{tp|p=32514689|t=2020. The potential of drug repositioning as a short-term strategy for the control and treatment of COVID-19 (SARS-CoV-2): a systematic review.|pdf=|usr=008}}
-{{tp|p=32446195|t=2020. Interactions of recommended COVID-19 drugs with commonly used psychotropics.|pdf=|usr=008}}
-{{tp|p=32399655|t=2020. Allogeneic cardiosphere-derived cells (CAP-1002) in critically ill COVID-19 patients: compassionate-use case series.|pdf=|usr=008}}
+{{tp|p=32399093|t=2020. Lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic.|pdf=|usr=008}}
 {{tp|p=32470547|t=2020. Targeting Neprilysin (NEP) pathways: A potential new hope to defeat COVID-19 ghost.|pdf=|usr=008}}
-{{tp|p=32440566|t=2020. Employing drug delivery strategies to create safe and effective pharmaceuticals for COVID-19.|pdf=|usr=008}}
-{{tp|p=32458149|t=2020. Can Zn Be a Critical Element in COVID-19 Treatment?|pdf=|usr=008}}
 {{tp|p=32532623|t=2020. Fighting COVID-19: A quick review of diagnoses, therapies, and vaccines.|pdf=|usr=008}}
-{{tp|p=32426388|t=2020. Computation screening of narcissoside a glycosyloxyflavone for potential novel coronavirus 2019 (COVID-19) inhibitor.|pdf=|usr=008}}
-{{tp|p=32426387|t=2020. Artificial intelligence approach fighting COVID-19 with repurposing drugs.|pdf=|usr=008}}
-{{tp|p=32534226|t=2020. Monoclonal antibody as a potential anti-COVID-19.|pdf=|usr=008}}
-{{tp|p=32410772|t=2020. Emerging pharmacotherapies for COVID-19.|pdf=|usr=008}}
-{{tp|p=32519753|t=2020. The potential of cannabidiol in the COVID-19 pandemic: a hypothesis letter.|pdf=|usr=008}}
 {{tp|p=32383371|t=2020. Perspectives of Immune Therapy in Coronavirus Disease 2019.|pdf=|usr=008}}
-{{tp|p=32508168|t=2020. Effectiveness and safety of available treatments for COVID-19 during pregnancy: a critical review.|pdf=|usr=008}}
 {{tp|p=32401215|t=2020. Telehealth Home Support During COVID-19 Confinement for Community-Dwelling Older Adults With Mild Cognitive Impairment or Mild Dementia: Survey Study.|pdf=|usr=008}}
-{{tp|p=32410266|t=2020. Immunoregulation with mTOR inhibitors to prevent COVID-19 severity: A novel intervention strategy beyond vaccines and specific antiviral medicines.|pdf=|usr=008}}
-{{tp|p=32391920|t=2020. Consider TLR5 for new therapeutic development against COVID-19.|pdf=|usr=008}}
-{{tp|p=32422320|t=2020. p38 MAPK inhibition: A promising therapeutic approach for COVID-19.|pdf=|usr=008}}
-{{tp|p=32454981|t=2020. Current regulatory approaches for accessing potential COVID-19 therapies.|pdf=|usr=008}}
 {{tp|p=32468385|t=2020. Musings on the current state of COVID-19 modeling and reporting.|pdf=|usr=008}}
 {{tp|p=32435882|t=2020. Model based approach for estimating the dosage regimen of indomethacin a potential antiviral treatment of patients infected with SARS CoV-2.|pdf=|usr=008}}
-{{tp|p=32406687|t=2020. In Silico Exploration of the Molecular Mechanism of Clinically Oriented Drugs for Possibly Inhibiting SARS-CoV-2's Main Protease.|pdf=|usr=008}}
 {{tp|p=32452670|t=2020. Immunity-Boosting Spices and the Novel Coronavirus.|pdf=|usr=008}}
-{{tp|p=32525650|t=2020. Targeting SARS-CoV-2: Novel Source of Antiviral Compound(s) against COVID-19?|pdf=|usr=008}}
-{{tp|p=32534130|t=2020. EPO in Patients With COVID-19: More Than an Erythropoietic Hormone.|pdf=|usr=008}}
-{{tp|p=32525715|t=2020. Multigroup, Adaptively Randomized Trials Are Advantageous for Comparing Coronavirus Disease 2019 (COVID-19) Interventions.|pdf=|usr=008}}
 {{tp|p=32396382|t=2020. Myth Busters: Dietary Supplements and COVID-19.|pdf=|usr=008}}
-{{tp|p=32523147|t=2020. Anotaciones breves sobre el sindrome de liberacion de citocinas y el bloqueo terapeutico de la interleucina-6 en SARS-CoV-2/COVID-19.|pdf=|usr=008}}
 {{tp|p=32523144|t=2020. Protocolo para la prevencion de arritmias ventriculares debido al tratamiento en pacientes con COVID-19.|pdf=|usr=008}}
 {{tp|p=32518135|t=2020. Paediatric treatment trials for COVID-19 are an ethical imperative.|pdf=|usr=008}}
@@ Zeile 274: / Zeile 248: @@
-{{tp|p=32533795|t=2020. Further aspects of doxycycline therapy in COVID-19.|pdf=|usr=008}}
-{{tp|p=32533990|t=2020. Is metformin ahead in the race as a repurposed host-directed therapy for patients with diabetes and COVID-19?|pdf=|usr=008}}
-{{tp|p=32529218|t=2020. Statin therapy in COVID-19 infection: much more than a single pathway.|pdf=|usr=008}}
 {{tp|p=32520031|t=2020. In silico evaluation of marine fish proteins as nutritional supplements for COVID-19 patients.|pdf=|usr=008}}
@@ Zeile 282: / Zeile 256: @@
-{{tp|p=32380847|t=2020. Cannabis in the Time of Coronavirus Disease 2019: The Yin and Yang of the Endocannabinoid System in Immunocompetence.|pdf=|usr=008}}
 {{tp|p=32516380|t=2020. Covid-19's Impact on Podiatry in Chicago's Largest Public Hospital.|pdf=|usr=008}}
-{{tp|p=32515404|t=2020. Comprehensive overview of COVID-19 clinical trials.|pdf=|usr=008}}
-{{tp|p=32515383|t=2020. Treatment options in people with COVID19: Selecting the best armamentarium against the novel virus.|pdf=|usr=008}}
-{{tp|p=32395418|t=2020. An Update on Current Therapeutic Drugs Treating COVID-19.|pdf=|usr=008}}
-{{tp|p=32391242|t=2020. A Precision Medicine Approach to SARS-CoV-2 Pandemic Management.|pdf=|usr=008}}
-{{tp|p=32467020|t=2020. Acute inflammation and pathogenesis of SARS-CoV-2 infection: Cannabidiol as a potential anti-inflammatory treatment?|pdf=|usr=008}}
-{{tp|p=32425691|t=2020. ISEV and ISCT statement on EVs from MSCs and other cells: considerations for potential therapeutic agents to suppress COVID-19.|pdf=|usr=008}}
-{{tp|p=32385829|t=2020. COVID-19 and off label use of drugs: an ethical viewpoint.|pdf=|usr=008}}
-{{tp|p=32449265|t=2020. Apremilast as a potential treatment option for COVID-19: no symptoms of infection in a psoriatic patient.|pdf=|usr=008}}
-{{tp|p=32418299|t=2020. The COVID-19 chemoprophylactic conundrum: Are we limiting available resources?|pdf=|usr=008}}
-{{tp|p=32406143|t=2020. Could patients taking isotretinoin therapy be immune against SARS-CoV-2?|pdf=|usr=008}}
 {{tp|p=32390307|t=2020. Practical tips for using masks in the COVID-19 pandemic.|pdf=|usr=008}}
@@ Zeile 312: / Zeile 279: @@
-{{tp|p=32451923|t=2020. The G-Quadruplex/Helicase World as a Potential Antiviral Approach Against COVID-19.|pdf=|usr=008}}
-{{tp|p=32523611|t=2020. A brief note on randomized controlled trials and compassionate/off-label use of drugs in the early phases of the COVID-19 pandemic.|pdf=|usr=008}}
-{{tp|p=32499832|t=2020. Pharmacological treatment of COVID-19: lights and shadows.|pdf=|usr=008}}
-{{tp|p=32520599|t=2020. Povidone-Iodine Use in Sinonasal and Oral Cavities: A Review of Safety in the COVID-19 Era.|pdf=|usr=008}}
-{{tp|p=32469436|t=2020. Physicochemical properties of SARS-CoV-2 for drug targeting, virus inactivation and attenuation, vaccine formulation and quality control.|pdf=|usr=008}}
 {{tp|p=32378805|t=2020. COVID-19 and toxicity from potential treatments: Panacea or poison.|pdf=|usr=008}}
 {{tp|p=32475694|t=2020. Reflexions autour d'une evolution favorable d'une COVID-19 chez un patient presentant une schizophrenie resistante et sous une association clozapine et paliperidone palmitate.|pdf=|usr=008}}
 {{tp|p=32482569|t=2020. Nutricion Clinica en tiempos de COVID-19.|pdf=|usr=008}}
-{{tp|p=32495654|t=2020. Targeting SARS-CoV-2 using polycomb inhibitors as antiviral agents.|pdf=|usr=008}}
-{{tp|p=32379302|t=2020. Cardiac safety and potential efficacy: two reasons for considering minocycline in place of azithromycin in COVID-19 management.|pdf=|usr=008}}
 {{tp|p=32518390|t=2020. Editorial: Nutrition and COVID-19.|pdf=|usr=008}}
@@ Zeile 330: / Zeile 295: @@
-{{tp|p=32414641|t=2020. The quality of the reported sample size calculation in clinical trials on COVID-19 patients indexed in PubMed.|pdf=|usr=008}}
-{{tp|p=32430428|t=2020. Factors associated with prolonged viral shedding and impact of Lopinavir/Ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection.|pdf=|usr=008}}
 {{tp|p=32398309|t=2020. Could the smoking gun in the fight against Covid-19 be the (rh) ACE2?|pdf=|usr=008}}
 {{tp|p=32398976|t=2020. siRNA could be a potential therapy for COVID-19.|pdf=|usr=008}}
-{{tp|p=32518634|t=2020. Lithium and coronaviral infections. A scoping review.|pdf=|usr=008}}
-{{tp|p=32518636|t=2020. A snapshot of the ongoing clinical research on COVID-19.|pdf=|usr=008}}
-{{tp|p=32395702|t=2020. The role of growth factor receptors in viral infections: An opportunity for drug repurposing against emerging viral diseases such as COVID-19?|pdf=|usr=008}}
-{{tp|p=32426374|t=2020. Cardiovascular Impairment in COVID-19: Learning From Current Options for Cardiovascular Anti-Inflammatory Therapy.|pdf=|usr=008}}
 {{tp|p=32425923|t=2020. Could the Inhibition of Endo-Lysosomal Two-Pore Channels (TPCs) by the Natural Flavonoid Naringenin Represent an Option to Fight SARS-CoV-2 Infection?|pdf=|usr=008}}
-{{tp|p=32390971|t=2020. The Current and Future State of Vaccines, Antivirals and Gene Therapies Against Emerging Coronaviruses.|pdf=|usr=008}}
 {{tp|p=32468851|t=2020. Facing the SARS-CoV-2 outbreak in the immunotherapy era.|pdf=|usr=008}}
 {{tp|p=32406749|t=2020. Oncology clinical trials in the time of COVID-19: how a pandemic can revolutionize patients' care.|pdf=|usr=008}}
-{{tp|p=32406253|t=2020. Bacillus Calmette Guerin (BCG) vaccination use in the fight against COVID-19 - what's old is new again?|pdf=|usr=008}}
-{{tp|p=32523109|t=2020. Molecular structure analyses suggest strategies to therapeutically target SARS-CoV-2.|pdf=|usr=008}}
-{{tp|p=32501513|t=2020. How to Rapidly Determine First-in-Children Dosing for COVID-19 Therapeutics.|pdf=|usr=008}}
-{{tp|p=32433861|t=2020. How to Discover Antiviral Drugs Quickly.|pdf=|usr=008}}
-{{tp|p=32515974|t=2020. Spiky Nanostructures with Geometry-matching Topography for Virus Inhibition.|pdf=|usr=008}}
-{{tp|p=32514101|t=2020. First antibody against COVID-19 spike protein enters phase I.|pdf=|usr=008}}
-{{tp|p=32529963|t=2020. Can lactoferrin boost human immunity against COVID-19?|pdf=|usr=008}}
 {{tp|p=32535509|t=2020. COVID-19, interferons, and depression: A commentary.|pdf=|usr=008}}
-{{tp|p=32409452|t=2020. Pandemic could add noise to clinical trial data.|pdf=|usr=008}}
-{{tp|p=32527823|t=2020. Aggregating data from COVID-19 trials.|pdf=|usr=008}}
-{{tp|p=32527819|t=2020. Can existing live vaccines prevent COVID-19?|pdf=|usr=008}}
-{{tp|p=32520641|t=2020. Re: "Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19" by Sengupta et al.|pdf=|usr=008}}
-{{tp|p=32520639|t=2020. Response to Kim et al. re: "Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19".|pdf=|usr=008}}
@@ Zeile 372: / Zeile 320: @@
 {{tp|p=32470338|t=2020. MORTALITY FROM COVID-19 INCREASES WITH UNSATURATED FAT, AND MAY BE REDUCED BY EARLY CALCIUM AND ALBUMIN SUPPLEMENTATION.|pdf=|usr=008}}
-{{tp|p=32446698|t=2020. Famotidine Use is Associated with Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study.|pdf=|usr=008}}
-{{tp|p=32427166|t=2020. Natural experiment concept to accelerate the Re-purposing of existing therapeutics for Covid-19.|pdf=|usr=008}}
@@ Zeile 390: / Zeile 338: @@
-{{tp|p=32476308|t=2020. Empirical Treatment and Prevention of COVID-19.|pdf=|usr=007}}
-{{tp|p=32466136|t=2020. Towards Precision Medicine: Inclusion of Sex and Gender Aspects in COVID-19 Clinical Studies-Acting Now before It Is Too Late-A Joint Call for Action.|pdf=|usr=007}}
-{{tp|p=32486229|t=2020. Investigation of Some Antiviral N-Heterocycles as COVID 19 Drug: Molecular Docking and DFT Calculations.|pdf=|usr=007}}
-{{tp|p=32481690|t=2020. Broad-Spectrum Coronavirus Fusion Inhibitors to Combat COVID-19 and Other Emerging Coronavirus Diseases.|pdf=|usr=007}}
-{{tp|p=32471278|t=2020. Pulmonary Delivery of Fenretinide: A Possible Adjuvant Treatment In COVID-19.|pdf=|usr=007}}
-{{tp|p=32471272|t=2020. Cannabinoid Receptor Type 2: A Possible Target in SARS-CoV-2 (CoV-19) Infection?|pdf=|usr=007}}
-{{tp|p=32443911|t=2020. Proteasome Inhibitors as a Possible Therapy for SARS-CoV-2.|pdf=|usr=007}}
 {{tp|p=32429572|t=2020. The Role of Lipid Metabolism in COVID-19 Virus Infection and as a Drug Target.|pdf=|usr=007}}
-{{tp|p=32429099|t=2020. Deubiquitinating Enzymes in Coronaviruses and Possible Therapeutic Opportunities for COVID-19.|pdf=|usr=007}}
 {{tp|p=32408699|t=2020. Essential Oils as Antiviral Agents. Potential of Essential Oils to Treat SARS-CoV-2 Infection: An In-Silico Investigation.|pdf=|usr=007}}
-{{tp|p=32392184|t=2020. Clinical trials for COVID-19 should include sex as a variable.|pdf=|usr=007}}
+{{tp|p=32455942|t=2020. Potential Therapeutic Targeting of Coronavirus Spike Glycoprotein Priming.|pdf=|usr=007}}
 {{tp|p=32457038|t=2020. Potential COVID-19 therapeutics from a rare disease: Weaponizing lipid dysregulation to combat viral infectivity.|pdf=|usr=007}}
@@ Zeile 412: / Zeile 355: @@
 {{tp|p=32475104|t=2020. Coronavirus Disease 2019 Presenting as Conjunctivitis.|pdf=|usr=007}}
-{{tp|p=32293020|t=2020. Palliativ farmakologisk behandling vid svar covid-19.|pdf=|usr=007}}
-{{tp|p=32444382|t=2020. Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets.|pdf=|usr=007}}
-{{tp|p=32442946|t=2020. inverted question markBCG versus COVID-19?|pdf=|usr=007}}
@@ Zeile 421: / Zeile 362: @@
-{{tp|p=32455942|t=2020. Potential Therapeutic Targeting of Coronavirus Spike Glycoprotein Priming.|pdf=|usr=007}}
-{{tp|p=32408547|t=2020. Virtual Screening of Natural Products against Type II Transmembrane Serine Protease (TMPRSS2), the Priming Agent of Coronavirus 2 (SARS-CoV-2).|pdf=|usr=007}}
-{{tp|p=32486364|t=2020. Nanomaterials and Nanotechnology-Associated Innovations against Viral Infections with a Focus on Coronaviruses.|pdf=|usr=007}}
-{{tp|p=32486488|t=2020. Nicotinamide Riboside-The Current State of Research and Therapeutic Uses.|pdf=|usr=007}}
-{{tp|p=32418757|t=2020. Pancreatic cancer: Does a short course of carbon ion radiotherapy worth during COVID-19 outbreak?|pdf=|usr=007}}
-{{tp|p=32423024|t=2020. The Rationale for Potential Pharmacotherapy of COVID-19.|pdf=|usr=007}}
-{{tp|p=32434254|t=2020. Challenges at the Time of COVID-19: Opportunities and Innovations in Antivirals from Nature.|pdf=|usr=007}}
+{{tp|p=32418757|t=2020. Pancreatic cancer: Does a short course of carbon ion radiotherapy worth during COVID-19 outbreak?|pdf=|usr=007}}
 {{tp|p=32505040|t=2020. The end of 'cordon sanitaire' in Wuhan: the role of non-pharmaceutical interventions against COVID-19.|pdf=|usr=007}}
-{{tp|p=32381590|t=2020. Ethics of controlled human infection to address COVID-19.|pdf=|usr=007}}
 {{tp|p=32472939|t=2020. Assessing the impact of non-pharmaceutical interventions on SARS-CoV-2 transmission in Switzerland.|pdf=|usr=007}}
-{{tp|p=32395792|t=2020. COVID-19: Main therapeutic options.|pdf=|usr=007}}
-{{tp|p=32507409|t=2020. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.|pdf=|usr=007}}
-{{tp|p=32486283|t=2020. Reporter Replicons for Antiviral Drug Discovery against Positive Single-Stranded RNA Viruses.|pdf=|usr=007}}
-{{tp|p=32397643|t=2020. Potential Drugs Targeting Early Innate Immune Evasion of SARS-Coronavirus 2 via 2'-O-Methylation of Viral RNA.|pdf=|usr=007}}
-{{tp|p=32485102|t=2020. Current Perspective of Antiviral Strategies against COVID-19.|pdf=|usr=007}}
-{{tp|p=32369098|t=2020. Understanding Observational Treatment Comparisons in the Setting of Coronavirus Disease 2019 (COVID-19).|pdf=|usr=007}}
-{{tp|p=32398377|t=2020. Reply to Kesici et al. and Zeng et al.: Blocking the virus and reducing the inflammatory damage in COVID-19.|pdf=|usr=007}}
-{{tp|p=32462848|t=2020. Interleukine-1 et blocage du COVID-19.|pdf=|usr=007}}
-{{tp|p=32495979|t=2020. Emergence of novel coronavirus and progress toward treatment and vaccine.|pdf=|usr=007}}
@@ Zeile 461: / Zeile 396: @@
 {{tp|p=32500793|t=2020. Repurposing Nimesulide, a Potent Inhibitor of the B0AT1 Subunit of the SARS-CoV-2 Receptor, as a Therapeutic Adjuvant of COVID-19.|pdf=|usr=007}}
-{{tp|p=32433189|t=2020. Important interactions of immunosuppressants with experimental therapies for novel coronavirus disease (COVID-19): how to act.|pdf=|usr=007}}
-{{tp|p=32473596|t=2020. Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research.|pdf=|usr=007}}
-{{tp|p=32391659|t=2020. [Pharmaceutical care for severe and critically ill patients with COVID-19].|pdf=|usr=007}}
@@ Zeile 475: / Zeile 407: @@
-{{tp|p=32057209|t=2020. [Pharmacotherapeutics for the New Coronavirus Pneumonia].|pdf=|usr=007}}
-{{tp|p=32397700|t=2020. [Analysis of application of herd immunity as a control strategy for COVID-19].|pdf=|usr=007}}
-{{tp|p=32473600|t=2020. Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients.|pdf=|usr=007}}
 {{tp|p=32491981|t=2020. Nonpharmaceutical Measures for Pandemic Influenza in Nonhealthcare Settings-International Travel-Related Measures.|pdf=|usr=007}}
 {{tp|p=32487283|t=2020. Effect of Nonpharmaceutical Interventions on Transmission of Severe Acute Respiratory Syndrome Coronavirus 2, South Korea, 2020.|pdf=|usr=007}}
-{{tp|p=32490731|t=2020. Targeting SARS-CoV-2 Receptors as a Means for Reducing Infectivity and Improving Antiviral and Immune Response: An Algorithm-based Method For Overcoming Resistance To Antiviral Agents.|pdf=|usr=007}}
 {{tp|p=32403995|t=2020. Development of multi-specific humanized llama antibodies blocking SARS-CoV-2/ACE2 interaction with high affinity and avidity.|pdf=|usr=007}}
-{{tp|p=32499303|t=2020. Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series.|pdf=|usr=007}}
-{{tp|p=32496239|t=2020. Potential pharmacological agents for COVID-19.|pdf=|usr=007}}
 {{tp|p=32496237|t=2020. AYUSH for COVID-19: Science or Superstition?|pdf=|usr=007}}
-{{tp|p=32454489|t=2020. JAK Inhibition with Methotrexate as Treatment for COVID-19 Is a Double-Edged Sword.|pdf=|usr=007}}
-{{tp|p=32392562|t=2020. JAK Inhibition as a New Treatment Strategy for Patients with COVID-19.|pdf=|usr=007}}
-{{tp|p=32510105|t=2020. COVID-19: A Personalized Cardiometabolic Approach for Reducing Complications and Costs. The Role of Aging beyond Topics.|pdf=|usr=007}}
-{{tp|p=32505909|t=2020. Ursodeoxycholic acid as a candidate therapeutic to alleviate and/or prevent COVID-19-associated cytokine storm.|pdf=|usr=007}}
-{{tp|p=32492560|t=2020. Is the anti-filarial drug diethylcarbamazine useful to treat COVID-19?|pdf=|usr=007}}
 {{tp|p=32460209|t=2020. The effect of potential therapeutic agents on QT interval in patients with COVID-19 Infection: The importance of close monitoring and correction of electrolytes.|pdf=|usr=007}}
-{{tp|p=32454510|t=2020. Potential Immunoregulatory and Antiviral/SARS-CoV-2 Activities of Nitric Oxide.|pdf=|usr=007}}
 {{tp|p=32487990|t=2020. Modeling mitigation of influenza epidemics by baloxavir.|pdf=|usr=007}}
@@ Zeile 509: / Zeile 439: @@
-{{tp|p=32442323|t=2020. Curcumin as a potential treatment for COVID-19.|pdf=|usr=007}}
-{{tp|p=32430996|t=2020. Potential effects of curcumin in the treatment of COVID-19 infection.|pdf=|usr=007}}
-{{tp|p=32503877|t=2020. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19.|pdf=|usr=007}}
-{{tp|p=32492211|t=2020. Lopinavir/ritonavir and interferon combination therapy may help shorten the duration of viral shedding in patients with COVID-19: a retrospective study in two designated hospitals in Anhui, China.|pdf=|usr=007}}
-{{tp|p=32492205|t=2020. COVID-19 patients benefit from early antiviral treatment: a comparative, retrospective study.|pdf=|usr=007}}
-{{tp|p=32421836|t=2020. Potential pharmacological perspectives for the treatment/prevention of the SARS-COV-2 infection in opioid dependent patients.|pdf=|usr=007}}
-{{tp|p=32427774|t=2020. Early Outcomes with Utilization of Tissue Plasminogen Activator in COVID-19 Associated Respiratory Distress: A series of five cases.|pdf=|usr=007}}
-{{tp|p=32427277|t=2020. Need for Transparency and Reliable Evidence in Emergency Use Authorizations for Coronavirus Disease 2019 (COVID-19) Therapies.|pdf=|usr=007}}
-{{tp|p=32495940|t=2020. Probiotics and COVID-19: is there any link?|pdf=|usr=007}}
-{{tp|p=32504751|t=2020. A novel role of nifuroxazide in attenuation of sepsis-associated acute lung and myocardial injuries; role of TLR4/NLPR3/IL-1beta signaling interruption.|pdf=|usr=007}}
-{{tp|p=32505910|t=2020. Novel therapeutic targets for SARS-CoV-2-induced acute lung injury: Targeting a potential IL-1beta/neutrophil extracellular traps feedback loop.|pdf=|usr=007}}
-{{tp|p=32502901|t=2020. Ribosomal proteins as a possible tool for blocking SARS-COV 2 virus replication for a potential prospective treatment.|pdf=|usr=007}}
-{{tp|p=32505070|t=2020. Nebulized Lidocaine in COVID-19, An Hypothesis.|pdf=|usr=007}}
-{{tp|p=32369285|t=2020. A Trial of Lopinavir-Ritonavir in Covid-19.|pdf=|usr=007}}
-{{tp|p=32369284|t=2020. A Trial of Lopinavir-Ritonavir in Covid-19.|pdf=|usr=007}}
-{{tp|p=32369283|t=2020. A Trial of Lopinavir-Ritonavir in Covid-19.|pdf=|usr=007}}
-{{tp|p=32369282|t=2020. A Trial of Lopinavir-Ritonavir in Covid-19.|pdf=|usr=007}}
-{{tp|p=32369281|t=2020. A Trial of Lopinavir-Ritonavir in Covid-19.|pdf=|usr=007}}
-{{tp|p=32438383|t=2020. Inhaled modified angiotensin converting enzyme 2 (ACE2) as a decoy to mitigate SARS-CoV-2 infection.|pdf=|usr=007}}
-{{tp|p=32325475|t=2020. The post-lockdown period should be used to acquire effective therapies for future resurgence in SARS-Cov-2 infections.|pdf=|usr=007}}
-{{tp|p=32393915|t=2020. Biggest COVID-19 trial tests repurposed drugs first.|pdf=|usr=007}}
-{{tp|p=32417850|t=2020. Drug researchers pursue new lines of attack against COVID-19.|pdf=|usr=007}}
-{{tp|p=32415300|t=2020. Biotech companies prepare for COVID-19 downturn.|pdf=|usr=007}}
-{{tp|p=32415251|t=2020. 15 drugs being tested to treat COVID-19 and how they would work.|pdf=|usr=007}}
-{{tp|p=32422645|t=2020. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.|pdf=|usr=007}}
-{{tp|p=32408336|t=2020. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets.|pdf=|usr=007}}
-{{tp|p=32415276|t=2020. The sprint to solve coronavirus protein structures - and disarm them with drugs.|pdf=|usr=007}}
-{{tp|p=32409766|t=2020. Dozens of coronavirus drugs are in development - what happens next?|pdf=|usr=007}}
-{{tp|p=32405023|t=2020. Coronavirus drugs trials must get bigger and more collaborative.|pdf=|usr=007}}
+{{tp|p=32438383|t=2020. Inhaled modified angiotensin converting enzyme 2 (ACE2) as a decoy to mitigate SARS-CoV-2 infection.|pdf=|usr=007}}
 {{tp|p=32512579|t=2020. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe.|pdf=|usr=007}}
-{{tp|p=32504019|t=2020. The coronavirus outbreak could make it quicker and easier to trial drugs.|pdf=|usr=007}}
-{{tp|p=32424192|t=2020. CRISPR tool scales up to interrogate a huge line-up of viral suspects.|pdf=|usr=007}}
-{{tp|p=32324361|t=2020. [Farmakoterapias lehetosegek SARS-CoV-2-fertozes/COVID-19-betegseg eseten]|pdf=|usr=007}}
-{{tp|p=32398330|t=2020. A Call for Pediatric COVID-19 Clinical Trials.|pdf=|usr=007}}
-{{tp|p=32423342|t=2020. COVID-19 pandemic: what can pharmaceutical formulation and drug delivery experts offer?|pdf=|usr=007}}
-{{tp|p=32393419|t=2020. Recent advances of therapeutic targets and potential drugs of COVID-19.|pdf=|usr=007}}
-{{tp|p=32472655|t=2020. Cytokine storm in COVID-19 and parthenolide: preclinical evidence.|pdf=|usr=007}}
 {{tp|p=32501634|t=2020. Can Hypericum perforatum (SJW) prevent cytokine storm in COVID-19 patients?|pdf=|usr=007}}
-{{tp|p=32488956|t=2020. Can concomitant use of zinc and curcumin with other immunity-boosting nutraceuticals be the arsenal against COVID-19?|pdf=|usr=007}}
-{{tp|p=32439730|t=2020. Use of specific antimicrobials for COVID-19: should we prescribe them now or wait for more evidence?|pdf=|usr=007}}
-{{tp|p=32116200|t=2020. COVID-19: Perspectives on the Potential Novel Global Threat.|pdf=|usr=007}}
-{{tp|p=32385052|t=2020. HiJAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19.|pdf=|usr=007}}
-{{tp|p=32381697|t=2020. The race is on for antibodies that stop the new coronavirus.|pdf=|usr=007}}
-{{tp|p=32381692|t=2020. Combination prevention for COVID-19.|pdf=|usr=007}}
-{{tp|p=32461212|t=2020. Reducing transmission of SARS-CoV-2.|pdf=|usr=007}}
-{{tp|p=32385101|t=2020. Rapid repurposing of drugs for COVID-19.|pdf=|usr=007}}
-{{tp|p=32327575|t=2020. NIH organizes hunt for drugs.|pdf=|usr=007}}
+{{tp|p=32116200|t=2020. COVID-19: Perspectives on the Potential Novel Global Threat.|pdf=|usr=007}}
-{{tp|p=32409433|t=2020. Antivirals for COVID-19.|pdf=|usr=007}}
@@ Zeile 585: / Zeile 479: @@
-{{tp|p=32420637|t=2020. Repurposing current therapeutics for treating COVID-19: A vital role of prescription records data mining.|pdf=|usr=007}}
 {{tp|p=32294756|t=2020. Intervencoes nao farmacologicas para o enfrentamento a epidemia da COVID-19 no Brasil.|pdf=|usr=007}}
-{{tp|p=32438473|t=2020. Prevention and treatment of COVID-19 disease by controlled modulation of innate immunity.|pdf=|usr=007}}
-{{tp|p=32512271|t=2020. An approach towards development of monoclonal IgY antibodies against SARS CoV-2 spike protein (S) using phage display method: A review.|pdf=|usr=007}}
 {{tp|p=32448098|t=2020. Structural and simulation analysis of hotspot residues interactions of SARS-CoV 2 with human ACE2 receptor.|pdf=|usr=007}}
-{{tp|p=32448085|t=2020. Repurposing approved drugs as inhibitors of SARS-CoV-2 S-protein from molecular modeling and virtual screening.|pdf=|usr=007}}
-{{tp|p=32431217|t=2020. Withanone and caffeic acid phenethyl ester are predicted to interact with main protease (M(pro)) of SARS-CoV-2 and inhibit its activity.|pdf=|usr=007}}
-{{tp|p=32469418|t=2020. Evaluation of potential therapeutic options for COVID-19.|pdf=|usr=007}}
-{{tp|p=32441805|t=2020. Severe Acute Lung Injury Related to COVID-19 Infection: A Review and the Possible Role for Escin.|pdf=|usr=007}}
-{{tp|p=32437001|t=2020. Intuitive Global Insight Into COVID-19 Clinical Research Activities-The "COVID-19 Map of Hope".|pdf=|usr=007}}
-{{tp|p=32472779|t=2020. Food protein-derived antihypertensive peptides in the COVID-19 pandemic: friends of foes?|pdf=|usr=007}}
-{{tp|p=32508069|t=2020. Therapeutic Temperature Modulation for a Critically Ill Patient with COVID-19.|pdf=|usr=007}}
-{{tp|p=32470199|t=2020. Metformin use amid coronavirus disease 2019 pandemic.|pdf=|usr=007}}
-{{tp|p=32458502|t=2020. Glycyrrhetinic acid and its derivatives as potential alternative medicine to relieve symptoms in nonhospitalized COVID-19 patients.|pdf=|usr=007}}
-{{tp|p=32458475|t=2020. Ratcheting down the virulence of SARS-CoV-2 in the COVID-19 pandemic.|pdf=|usr=007}}
 {{tp|p=32458425|t=2020. Compassionate use of hzVSF-v13 in two patients with severe COVID-19.|pdf=|usr=007}}
-{{tp|p=32437019|t=2020. Baricitinib: A chance to treat COVID-19?|pdf=|usr=007}}
 {{tp|p=32463459|t=2020. Prescription Fill Patterns for Commonly Used Drugs During the COVID-19 Pandemic in the United States.|pdf=|usr=007}}
-{{tp|p=32428941|t=2020. Potential Unconventional Medicines for the Treatment of SARS-CoV-2.|pdf=|usr=007}}
 {{tp|p=32498081|t=2020. Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).|pdf=|usr=007}}
-{{tp|p=32449669|t=2020. A perspective on modern advances for COVID-19 (SARS-CoV-2) therapeutics.|pdf=|usr=007}}
-{{tp|p=32495917|t=2020. Viral kinetics and factors associated with rapid viral clearance during lopinavir/ritonavir-based combination therapy in non-severe COVID-19 patients.|pdf=|usr=007}}
-{{tp|p=32427004|t=2020. Can 3D printing of oral drugs help fight the current COVID-19 pandemic (and similar crisis in the future)?|pdf=|usr=007}}
-{{tp|p=32452701|t=2020. An up-to-date overview of computational polypharmacology in modern drug discovery.|pdf=|usr=007}}
-{{tp|p=32447996|t=2020. Treatments in the COVID-19 pandemic: an update on clinical trials.|pdf=|usr=007}}
-{{tp|p=32475183|t=2020. Does lopinavir measure up in the treatment of COVID-19?|pdf=|usr=007}}
-{{tp|p=32282262|t=2020. Treatment considerations for coronavirus (COVID-19).|pdf=|usr=007}}
-{{tp|p=32469280|t=2020. COVID-19: Gene Transfer to the Rescue?|pdf=|usr=007}}
-{{tp|p=32423245|t=2020. The Impact of the COVID-19 Pandemic on the Biotech Industry.|pdf=|usr=007}}
-{{tp|p=32212981|t=2020. A Message to Our Community in the Midst of the COVID-19 Pandemic.|pdf=|usr=007}}
-{{tp|p=32501133|t=2020. Vaccine repurposing approach for preventing COVID 19: can MMR vaccines reduce morbidity and mortality?|pdf=|usr=007}}
-{{tp|p=32503817|t=2020. Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research.|pdf=|usr=007}}
-{{tp|p=32503816|t=2020. Oral Methioninase for Covid-19 Methionine-restriction Therapy.|pdf=|usr=007}}
-{{tp|p=32503814|t=2020. COVID-19: The Potential Role of Copper and N-acetylcysteine (NAC) in a Combination of Candidate Antiviral Treatments Against SARS-CoV-2.|pdf=|usr=007}}
-{{tp|p=32449676|t=2020. COVID-19: Pentoxifylline as a potential adjuvant treatment.|pdf=|usr=007}}
-{{tp|p=32468014|t=2020. Comprehensive analysis of drugs to treat SARSCoV2 infection: Mechanistic insights into current COVID19 therapies (Review).|pdf=|usr=007}}
@@ Zeile 655: / Zeile 535: @@
-{{tp|p=32443151|t=2020. Lopinavir pharmacokinetics in COVID-19 patients.|pdf=|usr=007}}
 {{tp|p=32462858|t=2020. Oxygen-ozone therapy as adjuvant in the current emergency in SARS-COV-2 infection: a clinical study.|pdf=|usr=007}}
 {{tp|p=32469279|t=2020. Withanone and Withaferin-A are predicted to interact with transmembrane protease serine 2 (TMPRSS2) and block entry of SARS-CoV-2 into cells.|pdf=|usr=007}}